Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, marking a significant step in Lantern's AI-driven precision oncology strategy.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies. This patient population represents a significant unmet medical need, as advanced bladder cancer often becomes resistant to existing treatments. By leveraging its proprietary RADR platform, Lantern aims to identify patients most likely to benefit from LP-184, potentially improving outcomes and reducing unnecessary side effects.
LP-184 is a novel acylfulvene derivative that targets DNA damage repair pathways. The drug has shown promise in preclinical studies and is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. The clearance from EMA allows Lantern to expand its clinical footprint into Europe, which could accelerate enrollment and data collection.
The announcement underscores the importance of biomarker-guided trials in oncology. By selecting patients with specific genetic markers, Lantern hopes to demonstrate a higher response rate and better tolerability compared to traditional chemotherapy. This approach aligns with the broader trend in precision medicine, where treatments are tailored to individual tumor characteristics.
Lantern Pharma's RADR platform, which integrates AI and machine learning, has been instrumental in identifying biomarker candidates and optimizing clinical trial design. The company's multi-agentic AI co-scientist platform, withZeta.ai, is also commercially available as a subscription-based research platform, representing a new revenue stream. With headquarters in Dallas, Texas, and an AI Center of Excellence in Bengaluru, India, Lantern is positioning itself at the forefront of AI-driven drug development.
The success of this trial could have significant implications for Lantern Pharma and the broader field of oncology. If LP-184 proves effective in biomarker-selected bladder cancer patients, it could pave the way for regulatory approvals and expand the company's pipeline. Moreover, it would validate the RADR platform's ability to identify predictive biomarkers, potentially accelerating the development of other therapies.
For more information, visit the full press release at https://ibn.fm/6ku4F and the company's newsroom at https://ibn.fm/LTRN.
